MISSISSAUGA, ON, Aug. 18 /CNW/ - AstraZeneca Canada Inc. announced today
that it has filed a New Drug Submission (NDS) for FluMist(R) (Influenza
Vaccine, Live Attenuated Intranasal) with Health Canada. Working in
partnership with its biologics subsidiary MedImmune, AstraZeneca Canada
intends to bring MedImmune's leading vaccine technology to Canadian patients
through its FluMist product, which is administered intranasally. The proposed
indication for FluMist is for the prevention of seasonal influenza.
The submission is based on data from 73 global clinical and U.S.
post-marketing studies of more than 141,000 subjects ranging in age from seven
weeks to 97 years and conducted in 38 countries. During the 2004 to 2005 flu
season, a large study was completed comparing FluMist, administered as a mist
sprayed into the nose, to the injectable flu shot. The study included more
than 8,000 children, of which more than 4,000 were between two to five years
of age and showed that the group of children who received FluMist had
significantly fewer cases of flu than the group who received the injectable
flu shot. (i)
"Every year, there is a significant medical and economic burden placed on
the Canadian health care system due to vaccine-preventable illnesses. We are
hopeful that our products may one day contribute to increased vaccination
rates and reduce that burden of illness," said Dr. Catriona McMahon, Vice
President, Medical Affairs. "As such, AstraZeneca Canada is pleased to submit
its first application for a vaccine product in Canada."
About Influenza in Canada
Influenza is the most common vaccine-preventable disease in the developed
world. According to the Public Health Agency of Canada, between 4,000 and
8,000 Canadians can die of influenza and its complications annually, depending
on the severity of the season.(i) According to Statistics Canada, the rate of
vaccination in Canada was 34 per cent in 2005(ii). Current guidelines from the
National Advisory Committee on Immunization (NACI) encourage annual influenza
vaccination for all Canadians.(iii)
AstraZeneca is a leading global pharmaceutical company with an extensive
product portfolio spanning six major therapeutic areas: gastrointestinal,
cardiovascular, infection, neuroscience, oncology, and respiratory. In Canada,
AstraZeneca employs approximately 1,050 employees and its headquarters are
located in Mississauga, Ontario. With a state-of-the-art drug discovery centre
based in Montreal, Quebec, AstraZeneca has also been designated one of the 50
Best Employers in Canada in the 2009 Globe and Mail, Report on Business
(R.O.B.) survey. For more information about AstraZeneca Canada, please visit:
MedImmune is a leading innovation-focused biotechnology company whose
mission is to provide better medicines to patients, new medical options for
physicians and rewarding careers to employees. Dedicated to advancing science
and medicine to help people live better lives, the company is focused on
infection, oncology, respiratory disease and inflammation,
cardiovascular/gastrointestinal disease and neuroscience. Headquartered in
Gaithersburg, Maryland, MedImmune has approximately 3,000 employees worldwide
and is the wholly owned biologics business for AstraZeneca PLC. MedImmune's
portfolio complements AstraZeneca's historic range of small molecule and
biologic compounds and products. For more information, visit MedImmune's Web
site at http://www.medimmune.com.
FluMist(R) is a registered trademark of MedImmune licensed to
(i) About Seasonal Influenza (Flu).
Accessed July 19, 2009.
(ii) Statistics Canada. The Daily, Tuesday, October 2, 2007. Study:
Trends in influenza vaccination in Canada.
Accessed July 14, 2009.
(iii) Public Health Agency of Canada. Statement on Influenza Vaccination
for the 2007-2008 Season. Canada Communicable Disease Report.
Accessed July 16, 2009.
For further information:
For further information: Jennifer Dolan, Edelman, (416) 979-1120 ext.